A NEW PBS subsidy is available
this month for patients suffering
from malaria due to Plasmodium
falciparum.
Novartis’ Riamet (artemether
20mg with lumefantrine 120mg) is
the combination of two antimalarials
to treat acute,
uncomplicated malaria caused by
the parasite.
About 350 cases of malaria
reported in Australia are due to the
bug, with clinical studies showing a
96% cure rate after 28 days of
treatment with Riamet.
The tablets are indicated for
patients 12 years and older, but
registration and reimbursement of
a dispersible tablet for infants and
children has recently been
approved, with a PBS listing
expected later in the year.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 10
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.